Get the Stockscreener App
2.00
3.09%
0.06
Pre-market:
2.05
0.05
+2.50%
Avenue Therapeutics Inc stock is traded at $2.00, with a volume of 27,091.
It is up +3.09% in the last 24 hours and down -6.78% over the past month.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
See More
Previous Close:
$1.94
Open:
$1.92
24h Volume:
27,091
Relative Volume:
0.61
Market Cap:
$4.11M
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.3996
EPS:
-5.0046
Net Cash Flow:
$-12.45M
1W Performance:
+16.28%
1M Performance:
-6.78%
6M Performance:
-42.86%
1Y Performance:
-83.44%
1-Day Range:
$1.9102
$2.04
1-Week Range:
$1.72
$2.04
52-Week Range:
$1.60
$26.47
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
2.00 | 4.11M | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.70 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.33 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
615.00 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.31 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Drug Resistant Epilepsy Market Growth, Trends & Key Players - openPR
Subaru Corp Leads Third Avenue Value Fund's Strategic Moves in Q4 2024 - Yahoo Finance
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com Australia
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Postoperative Pain Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight - The Globe and Mail
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
SL Green Completes Loan Modification at One Madison Avenue - Yahoo Finance
APLT (Applied Therapeutics) Enterprise Value : $139.31 Mil (As of Dec. 01, 2024) - GuruFocus.com
Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Avenue Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
APLT (Applied Therapeutics) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Avenue Therapeutics stock hits 52-week low at $1.68 - Investing.com
Avenue Therapeutics Inc (ATXI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Ther - GuruFocus.com
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Canadian North Resources Inc. Announces Appointment Of Henderson Tse To The Board Of Directors - The Manila Times
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Expedia faces threat from tepid growth in 2025, Deutsche Bank says after downgrade - Investing.com
Avenue Therapeutics director Jay Kranzler sells $136 in stock - Investing.com India
Avenue Therapeutics director Jay Kranzler sells $136 in stock By Investing.com - Investing.com UK
APLT (Applied Therapeutics) Cash From Other Investing Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Drug Resistant Epilepsy Market Size, Industry Analysis, - openPR
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
NYC officials envision turning Fifth Avenue into a grand boulevard | Company Business News - Mint
Avenue Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Avenue Therapeutics stock hits 52-week low at $1.89 - Investing.com
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - Business Wire
DMart Q2 Results: Avenue Supermarts net profit rises 5.77% to ₹659.58 crore, revenue up 14.41% YoY | Company Business News - Mint
B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga
IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Park Avenue Securities LLC - Defense World
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - StockTitan
Avenue Therapeutics stock hits 52-week low at $2.17 By Investing.com - Investing.com South Africa
Avenue Therapeutics stock hits 52-week low at $2.17 - Investing.com
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC - Yahoo Finance
Avenue Therapeutics director buys shares worth $1,249 By Investing.com - Investing.com South Africa
Avenue Therapeutics director buys shares worth $1,249 - Investing.com India
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Frazier Life Sciences Management L.P. Increases Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Avenue Therapeutics grants stock units to top executives By Investing.com - Investing.com Canada
Avenue Therapeutics grants stock units to top executives - Investing.com India
Avenue Therapeutics Incentive Plan Awards Key Executives - TipRanks
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Avenue Therapeutics stock hits 52-week low at $2.23 By Investing.com - Investing.com Canada
Avenue Therapeutics stock hits 52-week low at $2.23 - Investing.com
Avenue Supermart shares rise 1.49% as Sensex climbs - The Economic Times
Avenue Supermart rises 1.49% as Sensex climbs - The Economic Times
Share price of Avenue Supermart falls as Sensex gains 251.05 points - The Economic Times
Victory Capital Management Inc. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avenue Therapeutics Inc Stock (ATXI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KRANZLER JAY D | Director |
Nov 05 '24 |
Sale |
2.24 |
61 |
137 |
559 |
| KRANZLER JAY D | Director |
Sep 30 '24 |
Buy |
2.50 |
497 |
1,242 |
620 |
| KRANZLER JAY D | Director |
Sep 27 '24 |
Buy |
2.40 |
3 |
7 |
123 |
0.48%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):